• Nora Strong, Grant Meeks, Sunil A Sheth, Louise McCullough, Julian A Villalba, Chunfeng Tan, Andrew Barreto, Audrey Wanger, Michelle McDonald, Peter Kan, Hashem Shaltoni, Jose Campo Maldonado, Victoria Parada, Ameer E Hassan, Sarah Reagan-Steiner, Tom Chiller, Jeremy A W Gold, Dallas J Smith, and Luis Ostrosky-Zeichner.
• From McGovern Medical School, University of Texas Health Science Center at Houston, Houston (N.S., G.M., S.A.S., L.M., C.T., A.B., A.W., M.M., L.O.-Z.), the University of Texas Medical Branch, Galveston (P.K., H.S.), and the University of Texas Rio Grande Valley-Harlingen, Harlingen (J.C.M., V.P., A.E.H.) - all in Texas; and the Infectious Diseases Pathology Branch, Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (J.A.V., S.R.-S.), and the Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases (T.C., J.A.W.G., D.J.S.), Centers for Disease Control and Prevention, Atlanta.
• N. Engl. J. Med. 2024 Feb 8; 390 (6): 522529522-529.

AbstractA multinational outbreak of nosocomial fusarium meningitis occurred among immunocompetent patients who had undergone surgery with epidural anesthesia in Mexico. The pathogen involved had a high predilection for the brain stem and vertebrobasilar arterial system and was associated with high mortality from vessel injury. Effective treatment options remain limited; in vitro susceptibility testing of the organism suggested that it is resistant to all currently approved antifungal medications in the United States. To highlight the severe complications associated with fusarium infection acquired in this manner, we report data, clinical courses, and outcomes from 13 patients in the outbreak who presented with symptoms after a median delay of 39 days.Copyright © 2024 Massachusetts Medical Society.

41 keywords...

hide…